ATG-008

DRUG3 trials

Sponsors

Antengene Therapeutics Limited, Sichuan University, Qi Zhou

Conditions

1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical CancerAdvanced Solid TumorHepatocellular Carcinoma

Phase 1

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

Sichuan UniversityAdvanced Solid Tumor

Start: 2020-04-23End: 2022-12-01Target: 60Updated: 2021-05-17

Phase 2

Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

TerminatedNCT03591965

Antengene Therapeutics LimitedHepatocellular Carcinoma

Start: 2018-08-07End: 2022-08-03Updated: 2023-07-10

A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )

Qi Zhou1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer

Start: 2021-08-03End: 2024-04-09Target: 96Updated: 2021-08-10

Related Papers

Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors.

2025-06-251 citations

A TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced cervical cancers with prior anti-PD-(L)1 therapy.

Journal of Clinical Oncology2025-05-28

A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort.

Journal of Clinical Oncology2024-06-012 citations

Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors.

2023-12-061 citations

A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-01

Abstract CT150: Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)

Cancer Research2023-04-141 citations

A phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2).

Journal of Clinical Oncology2022-06-011 citations